Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy and safety of n-3 polyunsaturated fatty acids (PUFA) treatment in obese children with nonalcoholic fatty liver disease (NAFLD). METHODS: One hundred and eight obese (body mass index (BMI) >95th percentile for age and sex) adolescents with NAFLD were included in the study. Mean age of the subjects was 13.8 ± 3.9 years (9-17 yrs). The diagnosis of NAFLD was based on the presence of liver steatosis with high transaminases. The subjects were randomly divided into two groups. Group 1 (PUFA group, n=52) received a 1000 mg dose of PUFA once daily for 12 months and lifestyle intervention. Group 2 (placebo group, n=56) received a recommended diet plus placebo and lifestyle intervention for 12 months. Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR) from fasting samples. RESULTS: BMI, fasting insulin levels and HOMA-IR values in both groups decreased significantly at the end of the study. In group 1, 67.8% of the patients had a decrease from baseline in the prevalence of steatosis (p<0.001). Frequency of elevated alanine aminotransferase (ALT) levels (39.2% to 14.2%; p<0.01) and elevated aspartate aminotransferase (AST) levels (25% to 17.8%; p=0.01) decreased significantly in the PUFA group. Following a 12-month diet plus placebo and lifestyle intervention treatment, 40.3% (21) of the patients in the placebo group also showed a decrease in frequency of steatosis (p=0.04) and slight decreases in frequency of elevated ALT levels (38.4% to 28.8%; p=0.01) and AST levels (30.7% to 28.8%; p>0.05). CONCLUSION: Our results indicated that n-3 PUFA treatment is safe and efficacious in obese children with NAFLD and can improve ultrasonographic findings and the elevated transaminase levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80467-0 · Cited by 1,169
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
N-3 polyunsaturated fatty acid regulation of hepatic gene transcription
Jump, D. B. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ffaf6a · Cited by 443 · cited 1×
“, PPARα, PPARγ, SREBP-1, ChREBP), can control key pathways involved in hepatic lipid metabolism (8,9).”
BackgroundPolyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression
Sekiya, M., Yahagi, N., Matsuzaka, T., Najima, Y., Nakakuki, M., Nagai, R., Ishibashi, S., Osuga, J.-I., Yamada, N., & Shimano, H. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.028 · Cited by 415 · cited 1×
“A diet enriched in PUFA was shown to improve insulin sensitivity and reduce intrahepatic triglycerides content and steatohepatitis, in both mice (16,17,18,19) and rats (7,20) with fatty liver.”
BackgroundHighly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis
Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E., Kiyosawa, K., & Aoyama, T. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31815591aa · Cited by 248 · cited 2×
“Tanaka et al (28) reported that treatment with EPA, one of the major components of n-3 PUFA, seems to be safe and efficacious for patients with NASH.”
BackgroundNagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., & Shibata, N. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.028 · Cited by 233 · cited 1×
“In more detail, PUFA are potent activators of PPARα, which up-regulates several genes involved in the stimulation of fatty acid oxidation (10,11,12,13) and down-regulates pro-inflammatory genes, such as TNF-α and IL-6 (14).”
BackgroundO’Keefe, J. H., Abuissa, H., Sastre, A., Steinhaus, D. M., & Harris, W. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.025 · Cited by 207 · cited 1×
“are able to reduce blood pressure (32) and that they have”
Background
Cited by
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“Dietary intake of monosaturated FAs found in foods like olive oil and avocado has been shown to improve insulin sensitivity and hepatic fat in prediabetic [150] and in paediatric patients with NAFLD [151].”
BackgroundOmega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
Chen, L.-H., Wang, Y.-F., Xu, Q.-H., & Chen, S.-S. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2016.12.009 · Cited by 72
Khorshidi, M., Hazaveh, Z. S., Alimohammadi-kamalabadi, M., Jamshidi, S., Moghaddam, O. M., Olang, B., Hatefi, S., Hosseini, A., Jamilian, P., Zarezadeh, M., et al. (2023) · Nutrition Journal · doi:10.1186/s12937-022-00826-5 · Cited by 22
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Komolafe, O., Buzzetti, E., Linden, A., Best, L. M., Madden, A. M., Roberts, D., Chase, T. J., Fritche, D., Freeman, S. C., Cooper, N. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013157.pub2 · Cited by 21
Metadata
- Authors
- Boyraz, M., Pirgon, Ö., Dündar, B., Çekmez, F., & Hatipoğlu, N.
- Venue
- Journal of Clinical Research in Pediatric Endocrinology
- Publisher
- Galenos Yayinevi
- Published
- 2015-06-05
- Volume
- 7
- Issue
- 2
- Pages
- 121-127
- ISSN
- 1308-5727 (ISSN-L)
- OpenAlex
- W2207100755
- Cited by
- 78
- References
- 7
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.4274/jcrpe.1749
- The paper
- Boyraz, M., Pirgon, Ö., Dündar, B., Çekmez, F., & Hatipoğlu, N. (2015). Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease. Journal of Clinical Research in Pediatric Endocrinology. https://doi.org/10.4274/jcrpe.1749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.